About RoukenBio
RoukenBio – CRO redefined. RoukenBio takes its tagline seriously - disrupting the traditional CRO model with a collaborative, personalised approach to drug discovery. With customers in over 27 countries, RoukenBio aims to become the most trusted research partner to biotherapeutic innovators globally. Backed by brilliant minds, RoukenBio offers a range of in vitro drug discovery services with specialist expertise across human immunology, bioanalytical, cell line engineering, molecular biology, bioassay development and safety and efficacy assessments. RoukenBio partners with therapeutic developers from early discovery, through IND-enabling pivotal data studies, to ‘GMP-ready’ potency assay creation. Working across inflammation, auto-immunity, immuno-oncology and oncology, their team focuses on novel and emerging therapeutic classes including antibodies, cell therapies, nanoparticles, small molecules, protein degraders, peptides, recombinant proteins, vaccines, antibody drug conjugates and more. RoukenBio embraces change and drives innovation with unique services, like the customisable inducible cell line platform, IndEx-2, to stay ahead of the curve. RoukenBio’s assay solutions recreate disease state pathologies as faithfully as possible, and combined with a thought-partner approach to research collaborations, the RoukenBio team uses their scientific empathy to propel their customer’s therapeutic development projects forward.
Leadership at RoukenBio
The team at the top of the org chart.
Andy Upsall
Founder & CEO
28 reports
Jennifer Lawson
Chief Operating Officer
6 reports
Agapitos Patakas
Chief Scientific Officer
11 reports
Alan McDonald
Chief Financial Officer
Michahaila Downie
People and Finance Director
Adele Hannigan
Chief Business Officer
6 reports